This is a working overview of HGF mimetic, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-01-05 and is reviewed periodically as new material appears.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic angiotensin IV analog | Peptidomimetic |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in DMSO; limited in water | Typical for small peptides |
| Storage | -20 °C, desiccated | Protect from light and moisture |
| Analytical method | HPLC with UV detection | Purity and identity checks |
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Short proteins can be synthesized chemically by a family of peptide synthesis methods. These rely on organic synthesis techniques such as chemical ligation to produce peptides in high yield. Chemical synthesis allows for the introduction of non-natural amino acids into polypeptide chains, such as attachment of fluorescent probes to amino acid side chains, (this can also be achieved via genetic engineering when producing recombinant proteins). These methods are useful in laboratory biochemistry and cell biology, though generally not for commercial applications. Chemical synthesis is inefficient for polypeptides longer than about 300 amino acids, and the synthesized proteins may not readily assume their native tertiary structure. Most chemical synthesis methods proceed from C-terminus to N-terminus, opposite the biological reaction.
Most animals and plants can synthesize vitamin C through a sequence of enzyme-driven steps, which convert monosaccharides to vitamin C. However, some mammals have lost the ability to synthesize vitamin C, notably simians and tarsiers. These make up one of two major primate suborders, haplorrhini, and this group includes humans. The strepsirrhini (non-tarsier prosimians) can make their vitamin C, and these include lemurs, lorises, pottos, and galagos. Ascorbic acid is also not synthesized by at least two species of caviidae, the capybara and the guinea pig. Certain birds and fish do not synthesize their vitamin C. All species that do not synthesize ascorbate require it in the diet. Deficiency causes scurvy in humans, and somewhat similar symptoms in other animals. Animals that can contract scurvy all lack the L-gulonolactone oxidase (GULO) enzyme, which is required in the last step of vitamin C synthesis. The genomes of these species contain GULO as pseudogenes, which serve as insight into the evolutionary past of the species.
Collagen alpha-1(V) chain is a protein that in humans is encoded by the COL5A1 gene. This gene encodes an alpha chain for one of the low abundance fibrillar collagens. Fibrillar collagen molecules are trimers that can be composed of one or more types of alpha chains. Type V collagen is found in tissues containing type I collagen and appears to regulate the assembly of heterotypic fibers composed of both type I and type V collagen. This gene product is closely related to type XI collagen and it is possible that the collagen chains of types V and XI constitute a single collagen type with tissue-specific chain combinations. Mutations in this gene are associated with Ehlers–Danlos syndrome, types I and II.
Sources: en.wikipedia.org
In January 2021, the United States designated the Houthis a terrorist organization, creating fears of an aid shortage in Yemen, but this stance was reversed a month later after Joe Biden became president. On 17 January 2022, Houthi missile and drone attacks on UAE industrial targets set fuel trucks on fire and killed three foreign workers. This was the first specific attack to which the Houthi admitted, and the first to result in deaths. A response led by Saudi Arabia included a 21 January air strike on a detention centre in Yemen, resulting in at least 70 deaths. Following the outbreak of the Gaza war, the Houthis began to fire missiles at Israel and to attack ships off Yemen's coast in the Red Sea, which they say is in solidarity with the Palestinians and aiming to facilitate entry of humanitarian aid into the Gaza Strip. On 31 October Houthi forces launched ballistic missiles at Israel, which were shot down by Israel's Arrow missile defense system. Israeli officials claimed that this was the first ever combat to occur in space. In order to end the attacks in the Red Sea, the Houthis demanded a ceasefire in Gaza and an end to Israel's blockade of the Gaza Strip. In January 2024, the United States and the United Kingdom conducted airstrikes against multiple Houthi targets in Yemen, and the United States designated the Houthi as a Specially Designated Global Terrorist (SDGT). In February 2026, the Houthis announced that they had resumed attacks on ships in response to the recent US and Israeli airstrikes on Iran.
==== Tissue regeneration ==== To repair and regenerate damaged tissue, nanogels have been explored to not only encapsulate drugs and growth factors for local administration, but also to serve as porous scaffolds at a tissue implantation site. Boron-containing temperature-responsive nanogels formed a solid scaffold upon injection into a critical bone defect and continued to induce the production of new osteoblast cells. To treat the effects of myocardial infarction, one in vivo study loaded temperature-responsive nanogels with cardiac stem cells and observed improved cardiac function through an increase in left ventricular ejection. Blood vessels have been successfully regenerated in an in vivo model of ischemia using nanogels to encapsulate vascular endothelial growth factors. Heparin-based nanogels loaded with growth factors have also been tested in the regeneration of the urethral muscle that causes urinary incontinence.
As the human-rights norms associated with the Conference on Security and Cooperation in Europe (CSCE) increasingly entered Soviet public discourse, elements within the Soviet leadership began to reassess the diplomatic significance of the CSCE process. This reassessment became visible during the negotiations of the Vienna Follow-up Meeting (1986–1989), where by 1988, the Soviet delegation demonstrated an increased willingness to compromise and relinquish several long-standing positions. The resulting agreements, which received unusually broad attention within Soviet society, illustrated how perestroika contributed to a transformation in Soviet perceptions of multilateral diplomacy and international human-rights norms. Consequently, perestroika and glasnost had ripple effects throughout the orbit of the Soviet world, including eventually making it impossible to reassert central control over Warsaw Pact member states without resorting to military force. These ideological initiatives were accompanied by a significant reduction in military spending—which had once constituted 25 percent of the Soviet Union's GDP—as Gorbachev moved resources to improve the Soviet economy and help deal with domestic social challenges.
The Trump administration has repeatedly deployed federal forces, including active-duty military personnel and federalised National Guard forces, into certain U.S. cities. Trump has given multiple explanations for the deployments, saying they are part of crackdowns on protests, civil unrest, crime, homelessness, and illegal immigration. The actions targeted Democratic Party-led cities and sparked significant controversy, with critics labeling them as abuses of power and potential violations of laws like the Posse Comitatus Act, which limits military involvement in domestic law enforcement. The moves came amidst broader expansions of the military's domestic use during the second Trump administration, and Trump's prior comments during his presidential campaign to use the military to end civil unrest and protests without consent from state governors and target "the enemy within".During the June 2025 Los Angeles protests against local immigration raids, Trump federalized the California National Guard and deployed them to Los Angeles along with 700 Marines under Joint Task Force 51. Declaring a crime emergency in August 2025, the Trump administration deployed 2,000 National Guard soldiers to Washington, D.C. In September 2025, Trump announced the deployment of 150 unarmed national guardsmen to Memphis, Tennessee, saying that the city "is deeply troubled". Their presence in Memphis started on October 1.
Sources: en.wikipedia.org
The Spartanburg Pellagra Hospital in Spartanburg, South Carolina, was the first facility in the United States dedicated to discovering the cause of pellagra. It was established in 1914 with a special Congressional appropriation to the U.S. Public Health Service and set up primarily for research. In 1915, Dr. Joseph Goldberger, assigned to study pellagra by the surgeon general of the United States, showed it was linked to diet by observing the outbreaks of pellagra in orphanages and mental hospitals. Goldberger noted that children between the ages of 6 and 12 (but not older or younger children at the orphanages) and patients at the mental hospitals (but not doctors or nurses) were the ones who seemed most susceptible to pellagra. Goldberger theorized that a lack of meat, milk, eggs, and legumes made those particular populations susceptible to pellagra. By modifying the diet served in these institutions with "a marked increase in the fresh animal and the leguminous protein foods," Goldberger was able to show that pellagra could be prevented. By 1926, Goldberger established that a diet that included these foods, or a small amount of brewer's yeast, prevented pellagra. Goldberger experimented on 11 prisoners (one was dismissed because of prostatitis). Before the experiment, the prisoners were eating the prison fare fed to all inmates at Rankin Prison Farm in Mississippi. Goldberger started feeding them a restricted diet of grits, syrup, mush, biscuits, cabbage, sweet potatoes, rice, collards, and coffee with sugar (no milk).
A Polish government-in-exile functioned throughout the war, and the Poles contributed to the Allied victory through participation in military campaigns on both the eastern and western fronts. The westward advances of the Soviet Red Army in 1944 and 1945 compelled Nazi Germany's forces to retreat from Poland, which led to the establishment of a satellite communist country, known from 1952 as the Polish People's Republic. The territorial adjustments mandated by the Allies at the end of World War II in 1945 shifted Poland's geographic centre of gravity towards the west, and the re-defined Polish lands largely lost their historic multi-ethnic character. By the late 1980s, the Polish reform movement Solidarity contributed to a peaceful transition from a planned communist economy to capitalism and a liberal parliamentary democracy. This process resulted in the creation of the modern Polish state, the Third Polish Republic, founded in 1989.
Soft balancing was developed in the 2000s to account for the contemporary anomaly of the unipolar unbalanced world. Thomas Mowle and David Sacko describe "soft balancing" as "balancing that does not balance at all." These theoretical efforts are counter-productive, since Realism and unipolarity are compatible and structural realism should rather develop a set of hypotheses for a unipolar world: "Scholars do not need to desperately search for signs of balancing, they do not need to soften balancing beyond recognition, and they do not need to stand to watch for the first glimmering of a new multipolar dawn." Campbell Craig explained the development of soft balancing theory on the Thomas Kuhn's three-stage model how scholarly communities respond to anomalies that seem clearly to defy their core theoretical predictions:
[peptide]-(2S)-2-hydroxyglycine = [peptide]-amide + glyoxylate This enzyme belongs to the family of lyases, specifically amidine lyases. The systematic name of this enzyme class is [peptide]-(2S)-2-hydroxyglycine peptidyl-amide-lyase (glyoxylate-forming). Other names in common use include α-hydroxyglycine amidating dealkylase, peptidyl-α-hydroxyglycine α-amidating lyase, HGAD, PGL, PAL, and peptidylamidoglycolate peptidylamide-lyase.
After earning his doctorate in biochemistry, Lehninger held various faculty positions at the University of Wisconsin–Madison and the University of Chicago. In 1952, he went to the Johns Hopkins School of Medicine, assuming the title of DeLamar Professor of the Department of Biological Chemistry. He served in this position until 1978, when he was appointed to the role of University Professor of Medical Sciences. He held this title until his death in 1986. 1948 – Paul-Lewis Award in Enzyme Chemistry 1951 – Guggenheim Fellowship 1956 – Elected to the National Academy of Sciences 1959 – Elected to the American Academy of Arts and Sciences 1969 – Remsen Award of the American Chemical Society 1970 – American Philosophical Society 1986 – Passano Foundation Award Forthcoming in New Dictionary of Scientific Biography
Sources: en.wikipedia.org
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.
No major drug regulatory agency has approved dihexa for human use. Published human clinical trials are absent, so its safety and efficacy are not established. It is commonly sold for laboratory research only.
It was developed from research on angiotensin IV analogs and peptide stability. The goal was to find compounds with better brain penetration and metabolic resistance. Early studies used rodent models rather than human participants.
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.